Results 161 to 170 of about 19,811 (179)

Screening for carbapenem-resistant Enterobacteriaceae: Who, When, and How?

Virulence, 2017
Sandra S Richter, Dror Marchaim
exaly  

Potential economic burden of carbapenem-resistant Enterobacteriaceae (CRE) in the United States

Clinical Microbiology and Infection, 2017
B Y Lee, Bruce Y Lee
exaly  

Clinical and laboratory considerations for the rapid detection of carbapenem-resistant Enterobacteriaceae

Virulence, 2017
Ritu Banerjee, Romney M Humphries
exaly  

Carbapenem-resistant Enterobacteriaceae: global action required

The Lancet Infectious Diseases, 2019
Federico, Perez, Robert A, Bonomo
openaire   +2 more sources

Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1.

Clinical Infectious Diseases, 2016
Ryan K Shields, Brian A Potoski, Ghady Haidar   +2 more
exaly  

CRISPR-Cas9-Mediated Carbapenemase Gene and Plasmid Curing in Carbapenem-Resistant Enterobacteriaceae

Antimicrobial Agents and Chemotherapy, 2020
Mingju Hao, Xiao-Ping Liao, Hong Du
exaly  

Carbapenem-Resistant Acinetobacter baumannii and Enterobacteriaceae in South and Southeast Asia

Clinical Microbiology Reviews, 2017
Li Yang Hsu, Anucha Apisarnthanarak, Erum Khan   +2 more
exaly  

Colistin-resistance gene mcr in clinical carbapenem-resistant Enterobacteriaceae strains in China, 2014–2019

Emerging Microbes and Infections, 2020
Hong Huang, Ning Dong, Lingbin Shu
exaly  

Antecedent Carbapenem Exposure as a Risk Factor for Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae and Carbapenemase-Producing Enterobacteriaceae

Antimicrobial Agents and Chemotherapy, 2019
Oon Tek Ng, Koh Cheng Thoon, Nancy Wen Sim Tee   +2 more
exaly  

Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae

Virulence, 2017
Elizabeth A Neuner, Jason C Gallagher
exaly